Category: St. Jude Medical
The U.S. Circuit Court of Appeals refuses to reopen the a patent infringement lawsuit brought by St. Jude Medical against AccessClosure and its artery closure technology.
Medtech titan St. Jude Medical's (NYSE:STJ) lost a bid to appeal its lawsuit against AccessClosure after a federal court refused to hear a patent infringement claim over artery closure devices.
St. Jude Medical halts the Enlightn IV trial of its renal denervation technology just a few months after getting the green light to begin enrollment.
St. Jude Medical (NYSE:STJ) is calling off the Enlightn IV trial of the next generation of its renal denervation technology, just a few months after it began.
Edwards Lifesciences shares slide more than 5% after the medical device company forecasts sales for its flagship Sapien replacement heart valve for next year that miss analysts' expectations.
A conservative forecast for 2014 sent shares of Edwards Lifesciences (NYSE:EW) down more than 5% yesterday and kept them flat today, as the medical device company said it expects more competition next year for its flagship Sapien replacement heart valve.
The board of Minnesota medtech titan St. Jude Medical approves a $700 million share buyback and a 25¢ Q4 dividend as it affirms its outlook for the rest of the fiscal year.
St. Jude Medical's (NYSE:STJ) announced that it has approval from its board of directors to buy back up to $700 million shares' worth of its outstanding common stock, reporting in tandem that it expects to meet its revenue and per-share earnings guidance for the year.
Medtronic's cardiac and vascular group president, Michael Coyle, questions CardioMEMS' implantable heart monitor, citing Medtronic's experience with its now-abandoned Chronicle monitor.
The Champion implantable heart monitor made by CardioMEMS might not prove as cost-effective as a non-invasive approach, at least according to Medtronic (NYSE:MDT) cardiac and vascular group president Michael Coyle.
St. Jude Medical launches another trial of its neurostimulation technology for treating chronic pain after its stock hits a 52-week high.
St. Jude Medical (NYSE:STJ), fresh off of a 52-week high for its share price, said it's launching another clinical trial of its neurostimulation technology for treating chronic pain.
St. Jude Medical launches a clinical trial of its Prodigy neurostimulation device for treating chronic pain.
St. Jude Medical (NYSE:STJ) said it launched a clinical trial of its Prodigy neurostimulator to examine the treatment of chronic pain.